1262787-83-6
Chemical Structure
Patritumab
Synonym(s): AMG-888; U3-1287
- CAS No.: 1262787-83-6
- Formula:N/A
- Molecular Weight:(146.86 kDa)
IUPAC Name: 5-(2-isobutyramido-[1,2,4]triazolo[1,5-a]pyridin-7-yl)-N-(1-phenylethyl)-1H-indole-3-carboxamide
SMILES: [Patritumab]
Biological Activity: Patritumab (Human Anti-ERBB3 Recombinant Antibody) is a neutralizing monoclonal antibody to ERBB3. Patritumab shows a synergy with Cetuximab (HY-P9905), potently inhibits the phosphorylation of EGFR, HER2, HER3, ERK, and AKT. Patritumab also induces cell apoptosis and suppresses the growth of pancreatic, non-small cell lung cancer, and colorectal cancer xenograft tumors[1].
| Cat. No. | Product Name | Purity | Description | Pricing | |||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
|
Patritumab | 99.28% | Patritumab (Human Anti-ERBB3 Recombinant Antibody) is a neutralizing monoclonal antibody to ERBB3. Patritumab shows a synergy with Cetuximab (HY-P9905), potently inhibits the phosphorylation of EGFR, HER2, HER3, ERK, and AKT. Patritumab also induces cell apoptosis and suppresses the growth of pancreatic, non-small cell lung cancer, and colorectal cancer xenograft tumors. | ||||||||||||||||||||
|
loading...
/
|
|||||||||||||||||||||||
Keywords
